Los Angeles-Diagnostic Products Corp., has been granted FDA approval to market four PSA immunoassays for prostate cancer detection: Immulite PSA, Immulite 2000 PSA, Immulite Third Generation PSA, and Immulite 2000 Third Generation PSA. The assays are intended for in vitro diagnostic use with the Immulite and Immulite 2000 immunoassay analyzers.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.